HLA-A2 adjuvant protocol
| Schedule | Arm1 (qw) | Arm2 (q3w) | Arm3 (qdx4 q3w) |
|---|---|---|---|
| Number of patients (%) | |||
| 31 (100) | 31 (100) | 33 (100) | |
| Sex | |||
| Male | 17 (55) | 16 (52) | 24 (73) |
| Female | 14 (45) | 15 (48) | 9 (27) |
| Age | |||
| 21–30 | 1 (3) | 2 (6) | 0 (0) |
| 31–40 | 6 (19) | 3 (10) | 4 (12) |
| 41–50 | 11 (35) | 8 (26) | 10 (30) |
| 51–60 | 9 (29) | 12 (39) | 8 (24) |
| 61–70 | 4 (13) | 5 (16) | 10 (30) |
| Over 70 | 0 (0) | 1 (3) | 1 (3) |
| Eligibility criteria | |||
| Resected primary | 6 (19) | 14 (45) | 5 (15) |
| Positive nodes | 19 (61) | 13 (42) | 23 (70) |
| Resected mets | 6 (19) | 4 (13) | 5 (15) |
| Number of positive lymph nodes | |||
| 0 | 12 (39) | 18 (5) | 10 (30) |
| 1–2 | 16 (52) | 9 (29) | 10 (30) |
| 3–4 | 2 (6) | 4 (13) | 5 (15) |
| 5–6 | 0 (0) | 0 (0) | 4 (12) |
| 7–8 | 0 (0) | 0 (0) | 3 (9) |
| 9–10 | 0 (0) | 0 (0) | 1 (3) |
| >10 | 1 (5) | 0 (0) | 0 (0) |